布洛芬诱导的多种固定药物喷发被重新挑战证实:一个案例报告和文献审查
Yoshihito Mima1, Masako Yamamoto1, Hiyo Obikane2
1Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo 164-8541, Japan.
Diagnostics (Basel, Switzerland)
|January 11, 2025
概括
固定的药物喷发 (FDE) 可能是由非处方药物引起的,例如布洛芬. 早期诊断和停止药物治疗对于预防严重反应至关重要,如史蒂文斯-约翰逊综合征 (SJS) 或有毒表皮解 (TEN).
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 固定的药物喷发 (FDE) 是由特定药物再暴露引发的复发性皮肤炎症.
- 它通常呈现为局部性病变,但可以表现为水泡或斑块.
- 效应器记忆CD8阳性T细胞在再次暴露时重新激活,导致先前损伤部位的炎症.
研究的目的:
- 报告一个多次布洛芬诱导的固定药物喷发病例.
- 突出与非处方药相关的诊断挑战.
- 审查布洛芬诱导的多重FDE病例,并讨论潜在的严重后果.
主要方法:
- 一个23岁的男性患有布洛芬诱导的FDE的病例报告.
- 诊断证实通过立即皮疹后ibuprofen和他的病理学.
- 对13个先前报告的布洛芬诱导多重FDE病例的综述.
主要成果:
- 患者在服用伊布罗芬后出现了多次FDE.
- 组织病理学发现证实了FDE.
- 审查发现了13例布洛芬诱导的多重FDE病例,强调了它的发生.
结论:
- 包括布洛芬在内的非处方药可以导致多重FDE.
- 在FDE中不受控制的炎症可以升级为严重的反应,如史蒂文斯-约翰逊综合征 (SJS) 或有毒表皮解 (TEN).
- 及时诊断和绝对停止使用违规药物对于管理FDE和预防严重后果至关重要.
相关概念视频
Allergic Drug Reactions
809
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
809
Dosage Regimen: Fixed Dose
1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K
Cross-reactivity
31.0K
Overview
31.0K
Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K


